Glioblastoma multiforme (GBM) is considered as the most aggressive of gliomas. Most patients of GBM die within less than a year of their disease and presently no treatment procedure has been able to extend the survival span of patients This characteristic of glioblastoma multiforme has attracted a massive attention, however, GBM has evaded increasingly elaborate attempts of therapy discovery for more than 50 years. Nevertheless, several firms in the global glioblastoma multiforme treatment market are incessantly working towards providing more effective GBM treatment drugs and therapies.
According to the findings of a report published by Transparency Market Research (TMR), the global glioblastoma multiforme treatment market will demonstrate a healthy 11.4% CAGR during the forecast period from 2014 to 2022. In 2013, the global glioblastoma multiforme (GBM) treatment market was estimated at US$0.34 billion and is expected to be worth US$0.91 billion by end of the forecast period.
Browse The Market Research Report of Glioblastoma Multiforme Treatment (GBM) Market:
Robust R&D Environment to Drive the Global GBM Treatment Market
The robust R&D landscape in the global glioblastoma multiforme (GBM) treatment market will drive this industry to a great extent. Furthermore, companies are increasingly launching new therapies that are expected to offer effective treatment against GBM. This month (June 2015) several treatment for GBM were announced. These are:
- A team of Miller School of Medicine researchers have found out that the dark matter of the genome is crucial for the growth of GBM and a new type of drug which is being tested in GBM patients actually works by modifying the dark matter of genome.
- Another novel therapy is being practiced by doctors in Brisbane. This treatment involves combating viruses such as cytomegalovirus (CMV). Past research shows that half of the glioblastoma multiforme tumors carry evidence of CMV.
- Another therapy being practiced in Northern Colarado uses electric field therapy to slow GBM. Optune from Novocure is used in this therapy that is placed on the patient’s scalp.
Strong Pipeline to Benefit the Global GBM Treatment Market
The global glioblastoma multiforme (GBM) treatment market based on pipeline review is divided into early stage, i.e., phase I and II, and late stage, i.e., phase III. The phase III drugs include Rindopepimut (CDX-110), DCVax, and others. Some of the phase I and II drugs are SGT-53, ANG1005, Endostatin, Crenolanib, Cotara, AV0113, ARC-00, and ABT-414.
The FDA approved drugs in the global glioblastoma multiforme (GBM) treatment market include Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad), and Carmustine (BiCNU). Bevacizumab is the latest drug addition, while temozolomide led the global glioblastoma multiforme treatment market in 2013 due to its effectiveness when it is combined with surgery. In 2012, temozolomide lost the market exclusivity and bevacizumab acquired substantial market share as it is more effective than temozolomide.
The key companies operating in the global glioblastoma multiforme (GBM) treatment market are AbbVie, Activartis, Agenus, Arog Pharmacueticals, Cavion, Cortice Biosciences, Eisai, Exelixis, and OncoSynergy.
Browse Press Release of Glioblastoma Multiforme Treatment (GBM) Market:
Companies operating in the global glioblastoma multiforme (GBM) treatment market can benefit from focusing on development of biological and immunotherapy treatments. Furthermore, the development of novel drug delivery systems (NDDS) will also help firms to survive in the intensely competitive global market for glioblastoma multiforme treatment. Strategic partnerships and acquisitions can also help companies to penetrate in the global glioblastoma multiforme treatment market effectively.